# A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

> **NCT06194214** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT06194214
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-11
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06194214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06194214, "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06194214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*